These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18978530)

  • 1. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.
    Ibrahim AS; Spellberg B; Edwards J
    Curr Opin Infect Dis; 2008 Dec; 21(6):620-5. PubMed ID: 18978530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Iron and invasive fungal infection].
    Álvarez F; Fernández-Ruiz M; Aguado JM
    Rev Iberoam Micol; 2013; 30(4):217-25. PubMed ID: 23684655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferiprone iron chelation as a novel therapy for experimental mucormycosis.
    Ibrahim AS; Edwards JE; Fu Y; Spellberg B
    J Antimicrob Chemother; 2006 Nov; 58(5):1070-3. PubMed ID: 16928702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The iron chelator deferasirox protects mice from mucormycosis through iron starvation.
    Ibrahim AS; Gebermariam T; Fu Y; Lin L; Husseiny MI; French SW; Schwartz J; Skory CD; Edwards JE; Spellberg BJ
    J Clin Invest; 2007 Sep; 117(9):2649-57. PubMed ID: 17786247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus.
    Neupane GP; Kim DM
    Transfusion; 2009 Aug; 49(8):1762-9. PubMed ID: 19413741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.
    Reed C; Ibrahim A; Edwards JE; Walot I; Spellberg B
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3968-9. PubMed ID: 17000743
    [No Abstract]   [Full Text] [Related]  

  • 7. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.
    Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J
    Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lactoferrin, a potential iron-chelator as an adjunct treatment for mucormycosis - A comprehensive review.
    Singh A; Ahmad N; Varadarajan A; Vikram N; Singh TP; Sharma S; Sharma P
    Int J Biol Macromol; 2021 Sep; 187():988-998. PubMed ID: 34324905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect.
    Boelaert JR; Van Cutsem J; de Locht M; Schneider YJ; Crichton RR
    Kidney Int; 1994 Mar; 45(3):667-71. PubMed ID: 8196268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fob1 and Fob2 Proteins Are Virulence Determinants of Rhizopus oryzae via Facilitating Iron Uptake from Ferrioxamine.
    Liu M; Lin L; Gebremariam T; Luo G; Skory CD; French SW; Chou TF; Edwards JE; Ibrahim AS
    PLoS Pathog; 2015 May; 11(5):e1004842. PubMed ID: 25974051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of deferoxamine on different zygomycetes.
    Boelaert JR; de Locht M; Schneider YJ
    J Infect Dis; 1994 Jan; 169(1):231-2. PubMed ID: 8277194
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of Iron Chelators on the Formation and Development of Aspergillus fumigatus Biofilm.
    Nazik H; Penner JC; Ferreira JA; Haagensen JA; Cohen K; Spormann AM; Martinez M; Chen V; Hsu JL; Clemons KV; Stevens DA
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6514-20. PubMed ID: 26239975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in rhinocerebral mucormycosis: is iron the key?
    Bhargava P
    Neurol India; 2007; 55(4):416. PubMed ID: 18040125
    [No Abstract]   [Full Text] [Related]  

  • 14. Chelation of aluminum by combining deferasirox and deferiprone in rats.
    Saljooghi AS
    Toxicol Ind Health; 2012 Sep; 28(8):740-5. PubMed ID: 22025507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal combinations in Mucorales: A microbiological perspective.
    Schwarz P; Cornely OA; Dannaoui E
    Mycoses; 2019 Sep; 62(9):746-760. PubMed ID: 30830980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of iron and iron chelators in zygomycosis.
    Symeonidis AS
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():26-32. PubMed ID: 19754753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG.
    Gaboriau F; Leray AM; Ropert M; Gouffier L; Cannie I; Troadec MB; Loréal O; Brissot P; Lescoat G
    Biometals; 2010 Apr; 23(2):231-45. PubMed ID: 19997770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Host-iron assimilation: pathogenesis and novel therapies of mucormycosis.
    Ibrahim AS
    Mycoses; 2014 Dec; 57 Suppl 3(0 3):13-7. PubMed ID: 25178879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Posaconazole for the treatment of mucormycosis.
    Enoch DA; Aliyu SH; Sule O; Lewis SJ; Karas JA
    Int J Antimicrob Agents; 2011 Dec; 38(6):465-73. PubMed ID: 21782392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.
    Glickstein H; El RB; Shvartsman M; Cabantchik ZI
    Blood; 2005 Nov; 106(9):3242-50. PubMed ID: 16020512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.